About CrossBridge Bio
CrossBridge Bio is a company based in Houston (United States) founded in 2023 was acquired by Lilly in April 2026.. CrossBridge Bio has raised $10 million across 1 funding round from investors including Lilly, TMC Venture Fund and CE Ventures. CrossBridge Bio offers products and services including ADC Technology Platform, EGCit Linker, and Enzymatic Conjugation. CrossBridge Bio operates in a competitive market with competitors including Moderna, BeiGene, Incyte, MorphoSys and Dren Bio, among others.
- Headquarter Houston, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CrossBridge Bio
CrossBridge Bio offers a comprehensive portfolio of products and services, including ADC Technology Platform, EGCit Linker, and Enzymatic Conjugation. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for creating stable Antibody-Drug Conjugates to target cancer cells effectively.
Enzymatically cleavable linker enhancing ADC stability and targeted payload release.
Technique for precise integration of multi-arm linkers in ADC production.
Funding Insights of CrossBridge Bio
CrossBridge Bio has successfully raised a total of $10M through 1 strategic funding round. The most recent funding activity was a Seed round of $10 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Seed — $10.0M
-
First Round
First Round
(04 Nov 2024)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2024 | Amount | Seed - CrossBridge Bio | Valuation | TMC Venture Fund , CE Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in CrossBridge Bio
CrossBridge Bio has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, TMC Venture Fund and CE Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage Life-Sciences & Offline focused VC firm funding companies in the US
|
Founded Year | Domain | Location | |
|
Stage-agnostic tech-focused VC firm investing in geographies such as Israel and China
|
Founded Year | Domain | Location | |
|
Portal Innovations is engaged in funding life sciences startups.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by CrossBridge Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - CrossBridge Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Crossbridge Bio Comparisons
Competitors of CrossBridge Bio
CrossBridge Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, MorphoSys and Dren Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Crossbridge Bio
Frequently Asked Questions about CrossBridge Bio
When was CrossBridge Bio founded?
CrossBridge Bio was founded in 2023 and raised its 1st funding round 1 year after it was founded.
Where is CrossBridge Bio located?
CrossBridge Bio is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
Is CrossBridge Bio a funded company?
CrossBridge Bio is a funded company, having raised a total of $10M across 1 funding round to date. The company's 1st funding round was a Seed of $10M, raised on Nov 04, 2024.
What does CrossBridge Bio do?
CrossBridge Bio was founded in 2023 and is headquartered in Houston, United States. Antibody-Drug Conjugate therapeutics are developed within the biotechnology sector, with operations centered on a stable dual-linker payload technology. This technology supports various candidates, including the lead CB-120, which targets cancer treatment. Focus is placed on oncology applications through research and therapeutic development.
Who are the top competitors of CrossBridge Bio?
CrossBridge Bio's top competitors include Moderna, BeiGene and Regeneron Pharmaceuticals.
What products or services does CrossBridge Bio offer?
CrossBridge Bio offers ADC Technology Platform, EGCit Linker, and Enzymatic Conjugation.
Who are CrossBridge Bio's investors?
CrossBridge Bio has 7 investors. Key investors include Lilly, TMC Venture Fund, CE Ventures, Crescent Enterprises, and Portal Innovations.